The 94th Meeting of the Council for the Promotion of Cancer Control (Materials)

News Highlights

The 94th Meeting of the Council for the Promotion of Cancer Control discussed the future of cancer care delivery systems. Key focus areas included the development of regional hubs for cancer care collaboration, strengthening support for rare and pediatric cancers, and advancing genomic medicine. Enhancing palliative care to improve cancer patients’ quality of life (QOL) and establishing seamless support systems through multidisciplinary collaboration were also identified as crucial issues. These discussions suggest the need for strengthening and reorganizing cancer care functions in future healthcare institution management strategies and business succession plans.

Perspective from M&A Medical Editorial Department

The discussions at the 94th Council for the Promotion of Cancer Control extend beyond simply improving the quality of cancer care; they deeply impact healthcare institution management strategies, particularly regarding regional functional division and the future of M&A and business succession. The pursuit of specialization, such as developing hub hospitals and enhancing support for rare and pediatric cancers, suggests that maintaining such services independently may become difficult for small to medium-sized healthcare institutions. For instance, cases requiring advanced genomic medicine or multidisciplinary treatment necessitate significant investment in facilities and specialized personnel, often beyond the capacity of smaller entities. Consequently, strengthening regional collaboration, consolidating services in specialized institutions, and pursuing M&A for business succession can become viable options for providing optimal and continuous medical care to patients. This is particularly relevant for institutions where the chairman or director is aging and facing succession challenges. Early consideration of third-party succession through specialized advisors, rather than closure or business closure (haigyō), can lead to the preservation of regional medical services and stable management.

Points Raised by This News

• The specialization and consolidation of cancer care will impact the management of small to medium-sized hospitals, increasing the need for M&A and business succession.
• Addressing rare and pediatric cancers, and genomic medicine requires advanced facility and personnel investment, raising the hurdle for independent management.
• Strengthening regional cancer care collaboration will promote functional division and collaborative M&A among healthcare institutions.
• Improving QOL for cancer patients and ensuring seamless support increases the importance of multidisciplinary collaboration and can serve as a reference for organizational structure development during business succession.

Practical Questions Arising from This News

• Which healthcare institutions will be most significantly affected by the strengthening and reorganization of cancer care functions?
• What will be the role of our hospital as the development of regional hubs for cancer care collaboration progresses?
• What information (e.g., treatment outcomes, financial status) should we prepare when consulting with a specialized advisor?

If You Feel “Should I Consult Too?”

You should objectively evaluate your institution’s cancer care performance, the presence of specialists, and your regional collaboration status to determine if you can adapt to future changes in cancer care delivery systems. Especially if the chairman or director is elderly and facing succession issues, the discussions at this council provide a good opportunity to explore the possibility of business continuation through third-party succession, as an alternative to closure or廃業 (haigyō – business closure). To balance contribution to regional healthcare with management stability, we recommend early consultation with specialists.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics as a Small and Medium Enterprise Agency-certified M&A support institution, with a success fee-only basis. Consultations are handled with strict confidentiality. Free consultations are available here.